STAT+: The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug 

WASHINGTON — The Food and Drug Administration last month foisted a nearly impossible decision on insurers: Should they pay for an expensive new Alzheimer’s drug that may not actually help patients?

Normally, if a drug gets FDA approval, that means it has some benefit to patients. But the FDA decided to greenlight Biogen’s controversial drug Aduhelm without that guarantee.

Continue to STAT+ to read the full story…

STAT+: The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug 

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top